179 related articles for article (PubMed ID: 25286744)
1. The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype.
Markert C; Kastner IM; Hellwig R; Kalafut P; Schweizer Y; Hoffmann MM; Burhenne J; Weiss J; Mikus G; Haefeli WE
Basic Clin Pharmacol Toxicol; 2015 May; 116(5):423-8. PubMed ID: 25286744
[TBL] [Abstract][Full Text] [Related]
2. Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1.
Markert C; Hellwig R; Burhenne J; Hoffmann MM; Weiss J; Mikus G; Haefeli WE
Eur J Clin Pharmacol; 2013 Oct; 69(10):1785-93. PubMed ID: 23748747
[TBL] [Abstract][Full Text] [Related]
3. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
[TBL] [Abstract][Full Text] [Related]
4. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.
Mueller SC; Majcher-Peszynska J; Uehleke B; Klammt S; Mundkowski RG; Miekisch W; Sievers H; Bauer S; Frank B; Kundt G; Drewelow B
Eur J Clin Pharmacol; 2006 Jan; 62(1):29-36. PubMed ID: 16341856
[TBL] [Abstract][Full Text] [Related]
5. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity.
Fuchs I; Hafner-Blumenstiel V; Markert C; Burhenne J; Weiss J; Haefeli WE; Mikus G
Eur J Clin Pharmacol; 2013 Mar; 69(3):507-13. PubMed ID: 22968811
[TBL] [Abstract][Full Text] [Related]
6. Influence of St. John's wort on the steady-state pharmacokinetics and metabolism of bosentan.
Markert C; Ngui P; Hellwig R; Wirsching T; Kastner IM; Riedel KD; Burhenne J; Weiss J; Mikus G; Haefeli WE
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):328-36. PubMed ID: 24472406
[TBL] [Abstract][Full Text] [Related]
7. No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers.
Mueller SC; Majcher-Peszynska J; Mundkowski RG; Uehleke B; Klammt S; Sievers H; Lehnfeld R; Frank B; Thurow K; Kundt G; Drewelow B
Eur J Clin Pharmacol; 2009 Jan; 65(1):81-7. PubMed ID: 18762932
[TBL] [Abstract][Full Text] [Related]
8. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole.
Wang LS; Zhou G; Zhu B; Wu J; Wang JG; Abd El-Aty AM; Li T; Liu J; Yang TL; Wang D; Zhong XY; Zhou HH
Clin Pharmacol Ther; 2004 Mar; 75(3):191-7. PubMed ID: 15001970
[TBL] [Abstract][Full Text] [Related]
9. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
[TBL] [Abstract][Full Text] [Related]
10. The recovery time-course of CYP3A after induction by St John's wort administration.
Imai H; Kotegawa T; Tsutsumi K; Morimoto T; Eshima N; Nakano S; Ohashi K
Br J Clin Pharmacol; 2008 May; 65(5):701-7. PubMed ID: 18294328
[TBL] [Abstract][Full Text] [Related]
11. The influence of St John's Wort on CYP2C19 activity with respect to genotype.
Wang LS; Zhu B; Abd El-Aty AM; Zhou G; Li Z; Wu J; Chen GL; Liu J; Tang ZR; An W; Li Q; Wang D; Zhou HH
J Clin Pharmacol; 2004 Jun; 44(6):577-81. PubMed ID: 15145964
[TBL] [Abstract][Full Text] [Related]
12. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.
Harrison B; Magee MH; Mandagere A; Walker G; Dufton C; Henderson LS; Boinpally R
Clin Drug Investig; 2010; 30(12):875-885. PubMed ID: 20923245
[TBL] [Abstract][Full Text] [Related]
13. Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.
Adiwidjaja J; Boddy AV; McLachlan AJ
Clin Pharmacokinet; 2019 Jul; 58(7):911-926. PubMed ID: 30675694
[TBL] [Abstract][Full Text] [Related]
14. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
[TBL] [Abstract][Full Text] [Related]
15. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.
Goey AK; Mooiman KD; Beijnen JH; Schellens JH; Meijerman I
Cancer Treat Rev; 2013 Nov; 39(7):773-83. PubMed ID: 23394826
[TBL] [Abstract][Full Text] [Related]
16. The interaction between St John's wort and an oral contraceptive.
Hall SD; Wang Z; Huang SM; Hamman MA; Vasavada N; Adigun AQ; Hilligoss JK; Miller M; Gorski JC
Clin Pharmacol Ther; 2003 Dec; 74(6):525-35. PubMed ID: 14663455
[TBL] [Abstract][Full Text] [Related]
17. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme.
Markowitz JS; Donovan JL; DeVane CL; Taylor RM; Ruan Y; Wang JS; Chavin KD
JAMA; 2003 Sep; 290(11):1500-4. PubMed ID: 13129991
[TBL] [Abstract][Full Text] [Related]
18. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics.
Rengelshausen J; Banfield M; Riedel KD; Burhenne J; Weiss J; Thomsen T; Walter-Sack I; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2005 Jul; 78(1):25-33. PubMed ID: 16003289
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided.
Huppertz A; Werntz L; Meid AD; Foerster KI; Burhenne J; Czock D; Mikus G; Haefeli WE
Br J Clin Pharmacol; 2018 Dec; 84(12):2903-2913. PubMed ID: 30192025
[TBL] [Abstract][Full Text] [Related]
20. Effect of Tacrolimus Formulation (Prolonged-Release vs Immediate-Release) on Its Susceptibility to Drug-Drug Interactions with St. John's Wort.
Gümüs KS; Teegelbekkers A; Sauter M; Meid AD; Burhenne J; Weiss J; Blank A; Haefeli WE; Czock D
Clin Pharmacol Drug Dev; 2024 Mar; 13(3):297-306. PubMed ID: 38176912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]